Clin2
NCT07387094Likely a fitRecruiting

A study of XW003 for obesity with sleep apnea (no CPAP)

OSA - Obstructive Sleep ApneaObesity

Part of Brain & nervous system, Hormones & metabolism, Lungs & breathing clinical trials.

This trial tests an investigational weekly injection called XW003 for weight loss in people who have obesity and moderate-to-severe sleep apnea but do not use a CPAP machine. It aims to see if the drug can help with weight loss and improve sleep apnea without the need for a breathing machine.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
140 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • Your BMI must be 28 or higher.
  • You must have moderate to severe sleep apnea (AHI ≥15) confirmed by a sleep study.
  • You cannot have used a CPAP or other breathing machine for at least 4 weeks before the study, and you agree not to use one during the study.
  • You must have tried to lose weight by dieting at least once but it didn't work well enough.
  • You cannot have diabetes (except gestational diabetes in the past).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06931028Recruiting· Phase 3
Study of IBI362 for sleep apnea with obesity

This study tests an investigational medication (IBI362) to see if it can improve sleep apnea in people with obesity. You might qualify if you have moderate to severe sleep apnea and a BMI of 28 or higher, whether or not you currently use a CPAP machine.

Beijing
NCT07434050Recruiting· Phase 3
Study of XW003 for obesity with sleep apnea on CPAP therapy

This trial tests an investigational drug called XW003 to see if it helps people with obesity and obstructive sleep apnea who are already using a positive airway pressure (PAP) machine, like CPAP. It aims to improve weight loss and sleep apnea symptoms.

Shanghai, Shanghai Municipality
NCT07571005Recruiting· Phase 3
Testing a New Weight-Loss Medicine for Sleep Apnea

This study tests whether a new injectable medicine called NNC0487-0111 helps people with excess weight and moderate-to-severe obstructive sleep apnea (a condition where breathing stops repeatedly during sleep) lose weight and improve their sleep apnea—without needing a CPAP machine. The goal is to see if better weight loss can reduce sleep apnea symptoms.

San Diego, California
NCT07571109Recruiting· Phase 3
Weight Loss Medicine for Sleep Apnea on CPAP

This study tests a new injectable medicine (NNC0487-0111) to help people lose weight and improve obstructive sleep apnea (a breathing condition during sleep). You must already be using a CPAP machine (positive airway pressure device) for your sleep apnea.

Gilbert, Arizona
NCT07369011Recruiting· Phase 3
Study of eloralintide for sleep apnea with obesity

This study tests an investigational medication called eloralintide to see if it can improve sleep apnea in people who are overweight or have obesity. You will receive either the study drug or a placebo (inactive shot), and your sleep and weight will be monitored over time.

Cullman, Alabama
NCT07575932Recruiting· Phase 2
Testing New Weight Loss Medications PF-08653945 and PF-08653944

This study tests two new experimental medications designed to help adults lose weight and improve weight-related health conditions like high blood pressure and sleep apnea. Participants will take one of these medications to see if it's safe and effective.

Chandler, Arizona

Hear when a new Obesity trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.